Exploring acyclic nucleoside analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. 2008

Olga Familiar, and Hélène Munier-Lehmann, and Ana Negri, and Federico Gago, and Dominique Douguet, and Leen Rigouts, and Ana-Isabel Hernández, and María-José Camarasa, and María-Jesús Pérez-Pérez
Instituto de Química Médica (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.

In the search for novel inhibitors of the enzyme thymidine monophosphate kinase of Mycobacterium tuberculosis (TMPKmt), an attractive target for novel antituberculosis agents, we report herein the discovery of the first acyclic nucleoside analogues that potently and selectively inhibit TMPKmt. The most potent compounds in this series are (Z)-butenylthymines carrying a naphtholactam or naphthosultam moiety at position 4, which display K(i) values of 0.42 and 0.27 microM, respectively. Docking studies followed by molecular dynamics simulations performed to rationalize the interaction of this new family of inhibitors with the target enzyme revealed a key interaction between the distal substituent and Arg 95 in the target enzyme. The fact that these inhibitors are more easily synthesizable than previously identified TMPKmt inhibitors, together with their potency against the target enzyme, makes them attractive lead compounds for further optimization.

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D009281 Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
D009703 Nucleoside-Phosphate Kinase An enzyme that catalyzes reversible reactions of a nucleoside triphosphate, e.g., ATP, with a nucleoside monophosphate, e.g., UMP, to form ADP and UDP. Many nucleoside monophosphates can act as acceptor while many ribo- and deoxyribonucleoside triphosphates can act as donor. EC 2.7.4.4. Nucleoside Monophosphate Kinases,Kinase, Nucleoside-Phosphate,Kinases, Nucleoside Monophosphate,Monophosphate Kinases, Nucleoside,Nucleoside Phosphate Kinase
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Olga Familiar, and Hélène Munier-Lehmann, and Ana Negri, and Federico Gago, and Dominique Douguet, and Leen Rigouts, and Ana-Isabel Hernández, and María-José Camarasa, and María-Jesús Pérez-Pérez
September 2002, Journal of medicinal chemistry,
Olga Familiar, and Hélène Munier-Lehmann, and Ana Negri, and Federico Gago, and Dominique Douguet, and Leen Rigouts, and Ana-Isabel Hernández, and María-José Camarasa, and María-Jesús Pérez-Pérez
September 2003, Bioorganic & medicinal chemistry letters,
Olga Familiar, and Hélène Munier-Lehmann, and Ana Negri, and Federico Gago, and Dominique Douguet, and Leen Rigouts, and Ana-Isabel Hernández, and María-José Camarasa, and María-Jesús Pérez-Pérez
October 2002, Bioorganic & medicinal chemistry letters,
Olga Familiar, and Hélène Munier-Lehmann, and Ana Negri, and Federico Gago, and Dominique Douguet, and Leen Rigouts, and Ana-Isabel Hernández, and María-José Camarasa, and María-Jesús Pérez-Pérez
January 1998, Advances in experimental medicine and biology,
Olga Familiar, and Hélène Munier-Lehmann, and Ana Negri, and Federico Gago, and Dominique Douguet, and Leen Rigouts, and Ana-Isabel Hernández, and María-José Camarasa, and María-Jesús Pérez-Pérez
September 2021, Bioorganic & medicinal chemistry,
Olga Familiar, and Hélène Munier-Lehmann, and Ana Negri, and Federico Gago, and Dominique Douguet, and Leen Rigouts, and Ana-Isabel Hernández, and María-José Camarasa, and María-Jesús Pérez-Pérez
July 2006, Journal of medicinal chemistry,
Olga Familiar, and Hélène Munier-Lehmann, and Ana Negri, and Federico Gago, and Dominique Douguet, and Leen Rigouts, and Ana-Isabel Hernández, and María-José Camarasa, and María-Jesús Pérez-Pérez
January 2002, Chembiochem : a European journal of chemical biology,
Olga Familiar, and Hélène Munier-Lehmann, and Ana Negri, and Federico Gago, and Dominique Douguet, and Leen Rigouts, and Ana-Isabel Hernández, and María-José Camarasa, and María-Jesús Pérez-Pérez
April 2011, Bioorganic & medicinal chemistry,
Olga Familiar, and Hélène Munier-Lehmann, and Ana Negri, and Federico Gago, and Dominique Douguet, and Leen Rigouts, and Ana-Isabel Hernández, and María-José Camarasa, and María-Jesús Pérez-Pérez
December 2021, European journal of medicinal chemistry,
Olga Familiar, and Hélène Munier-Lehmann, and Ana Negri, and Federico Gago, and Dominique Douguet, and Leen Rigouts, and Ana-Isabel Hernández, and María-José Camarasa, and María-Jesús Pérez-Pérez
January 2006, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie,
Copied contents to your clipboard!